OTLK - Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
All information about trading OTLK - Outlook Therapeutics
OLTK - Form 8-K Regarding March 31, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - SCHEDULE 13G/A on May 15, 2025 - (TANG Companies)
All information about trading OTLK - Outlook Therapeutics
OTLK - FORM 10-Q For the quarterly period ended March 31, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - Selling Stockholders
All information about trading OTLK - Outlook Therapeutics
OTLK - Selling Stockholders 21,720,655 shares of Common Stock
All information about trading OTLK - Outlook Therapeutics
OTLK - Corporate Presentation April 15, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - Form 8-K Approves Retention Incentive for CFO
All information about trading OTLK - Outlook Therapeutics
OTLK - SCHEDULE 13G on April 10, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - Form 8-K, The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025.
All information about trading OTLK - Outlook Therapeutics
OTLK-Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
All information about trading OTLK - Outlook Therapeutics
OTLK - PROSPECTUS 21,720,655 shares of Common Stock
All information about trading OTLK - Outlook Therapeutics
OTLK - Outlook Therapeutics management to meet virtually with BTIG
All information about trading OTLK - Outlook Therapeutics
OTLK - FORM S-3 REGISTRATION STATEMENT - PROSPECTUS 21,720,655 shares of Common Stock
All information about trading OTLK - Outlook Therapeutics
OTLK - FORM 8-K Annual Meeting of Stockholders March , March 11, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - FORM 4/A - SUKHTIAN GHIATH M.
All information about trading OTLK - Outlook Therapeutics
OTLK - SCHEDULE 13D on March 12, 2025 - GMS VENTURES & INVESTMENTS
All information about trading OTLK - Outlook Therapeutics
OTLK - PROSPECTUS 7,074,637 shares of Common Stock
All information about trading OTLK - Outlook Therapeutics
OTLK - Corporate Presentation March 07, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - SCHEDULE 13G on March 03, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK - Announced that it has resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration.
All information about trading OTLK - Outlook Therapeutics
OTLK - FORM S-3 PROSPECTUS 7,074,637 shares of Common Stock
All information about trading OTLK - Outlook Therapeutics
OTLK - Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
All information about trading OTLK - Outlook Therapeutics
OTLK - ANALYST TARGET PRICES, on Feb 18th, 2025
All information about trading OTLK - Outlook Therapeutics
OTLK-BUYOUT - "MY VIEW OF PROFITS" at FEBRUARY 15, 2025
All information about trading OTLK - Outlook Therapeutics
